The Norwegian life sciences industry is evolving rapidly. Having previously operated in the shadow of successful company clusters in Sweden and Denmark, Norwegian life sciences companies are now increasingly being recognized in their own right and attracting attention and interest from all over the world.
Continued research and development (R&D) by research centres in hospitals and universities in Norway is expected to contribute to the further development of the life sciences industry over the next decade. We expect growth in all relevant segments and particularly within oncology. Arctic Securities has dedicated significant resources to the sector, and has been involved in most of the Norwegian transactions within the life sciences sector over the last years. We combine in-depth medical knowledge with capital markets competence across all product areas.